Amneal’s new management team is open to negotiating a major transaction, even as it looks to restore organic growth through a greater focus on differentiated generic and hybrid products.
Amneal Pharmaceuticals' newly installed management team under co-CEOs Chirag and Chintu Patel says it is open to evaluating potential merger and acquisition opportunities, “including transformational transactions”. However, the team’s immediate focus is on improving operational efficiencies and rationalizing costs.
Outlining plans to alleviate margin pressure , in part through better supply-chain management and facility utilization, Chirag – who will...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
